Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents
Pharmaceuticals · 13.10.2023 · 16 (10) · 1456
DOI: 10.3390/ph16101456 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 13.10.2023. Verfasst von Prasanna Anjaneyulu Yakkala und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. Die Arbeit wurde bisher 137-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology, Department of Science and Technology (DST), the Government of India, Russian Foundation for Basic Research.
Abstract (Originalsprache)
Topoisomerases are very important enzymes that regulate DNA topology and are vital for biological actions like DNA replication, transcription, and repair. The emergence and spread of cancer has been intimately associated with topoisomerase dysregulation. Topoisomerase inhibitors have consequently become potential anti-cancer medications because of their ability to obstruct the normal function of these enzymes, which leads to DNA damage and subsequently causes cell death. This review emphasizes the importance of topoisomerase inhibitors as marketed, clinical and preclinical anti-cancer medications. In the present review, various types of topoisomerase inhibitors and their mechanisms of action have been discussed. Topoisomerase I inhibitors, which include irinotecan and topotecan, are agents that interact with the DNA-topoisomerase I complex and avert resealing of the DNA. The accretion of DNA breaks leads to the inhibition of DNA replication and cell death. On the other hand, topoisomerase II inhibitors like etoposide and teniposide, function by cleaving the DNA-topoisomerase II complex thereby effectively impeding the release of double-strand DNA breaks. Moreover, the recent advances in exploring the therapeutic efficacy, toxicity, and MDR (multidrug resistance) issues of new topoisomerase inhibitors have been reviewed in the present review.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
- Department of Chemistry, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi 110062, India.
- Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Hyderabad Campus, Dist. Medchal, Hyderabad 500078, India.
- Telangana State Council of Science & Technology, Environment, Forests, Science & Technology Department, Hyderabad 500004, India.
ORCID-Profile: Prasanna Anjaneyulu Yakkala, Naveen Reddy Penumallu, Ahmed Kamal
Förderung
- Department of Science and Technology
- Department of Science and Technology (DST), the Government of India
- Russian Foundation for Basic Research
- National Research Foundation (NRF) of South Africa
- BRICS STI cooperation program
Zitieren
APA
Yakkala, P. A., Penumallu, N. R., Shafi, S., & Kamal, A. (2023). Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents. Pharmaceuticals, 16(10), 1456. https://doi.org/10.3390/ph16101456
Vancouver
Yakkala PA, Penumallu NR, Shafi S, Kamal A. Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents. Pharmaceuticals. 2023;16(10):1456. doi:10.3390/ph16101456
BibTeX
@article{Yakkala2023,
author = {Yakkala, Prasanna Anjaneyulu and Penumallu, Naveen Reddy and Shafi, Syed and Kamal, Ahmed},
title = {Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {10},
pages = {1456},
doi = {10.3390/ph16101456}
}
EUVIMED